clinical trial · NCT07293351
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Bristol-Myers Squibb·phase2·recruiting·n = 474
Advanced Renal Cell Carcinoma (RCC)PumitamigIpilimumabCabozantinibCasdatifan
brief summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of Pumitamig alone or in combination with other agents in participants with advanced Renal Cell Carcinoma (RCC)
started
Mar 26, 2026
primary completion
Nov 28, 2029
completion
Nov 26, 2031
last updated
Sep 23, 2026
official title
ROSETTA RCC-208: A Phase 1/2 Open-label, Multi-center, Randomized Study of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol